ASH: Mantle cell lymphoma patients see improved outcomes with oral combination of ibrutinib and venetoclax

MD Anderson-led Phase III trial demonstrates significantly improved progression-free survival and remission rates

2023-12-12

(Press-News.org) ABSTRACT: LBA-2

SAN DIEGO ― The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS) and achieved an overall remission rate in 82% of patients with relapsed/refractory mantle cell lymphoma (MCL), according to researchers at The University of Texas MD Anderson Cancer Center. Results from the Phase III SYMPATICO trial were presented at the 2023 American Society of Hematology (ASH) Annual Meeting.

At a median follow-up of 51.2 months, median PFS was 31.9 months with the combination compared to 22.1 months with ibrutinib plus placebo. PFS benefits were consistent across patient subgroups, including those with blastoid-variant or TP53-mutated MCL. On the combination arm, 54% of patients achieved a complete remission compared to 32% on the placebo arm, a significant improvement.

“We are very encouraged by the data from this trial and for our patients to have achieved remissions using this targeted therapy. This combination allowed us to attack the cancer cells in two ways, which made it harder for the tumor to find resistance,” said principal investigator Michael Wang, M.D., professor of Lymphoma & Myeloma.

This international, multi-center trial evaluated ibrutinib, a BTK inhibitor, paired with venetoclax, a BCL-2 inhibitor; the two work together to attack MCL cells. MCL is a rare type of non-Hodgkin lymphoma with about 4,000 new cases diagnosed each year in the U.S. Often is diagnosed at stage IV, MCL has an aggressive disease course. According to Wang, MCL is becoming more common as the population ages.

The trial enrolled 267 adults with relapsed/refractory MCL who had previously received at least one prior line of therapy. Patients were randomly assigned to receive ibrutinib and venetoclax or ibrutinib and placebo.

Side effects were manageable and consistent with previous studies. Grade 3 or higher adverse events occurred in 84% of patients treated with the combination and 76% of those on the placebo arm. The most common side effect experienced was neutropenia.

“I am encouraged by our findings as we work to identify effective, targeted, chemo-free treatment options for patients with MCL,” Wang said. “We look forward to longer follow-up data from this trial to determine the best therapeutic approach for these patients. This is a milestone achievement for our patients with MCL.”

The trial was supported by AbbVie. A complete list of collaborating authors and their disclosures can be found with the abstract.

Read this press release in the MD Anderson Newsroom.

END

ELSE PRESS RELEASES FROM THIS DATE:

New test predicts risk of cognitive dysfunction in older surgery patients

2023-12-12

DURHAM, N.C. – Identifying an older patient who is at risk for post-operative cognitive dysfunction might be done in the blink of an eye – literally. Researchers at Duke Health found that a simple EEG measurement detects a signal of cognitive vulnerability when patients are asked to close, then open their eyes. Conducted prior to surgery, the non-invasive readout of brain waves helps predict which patients are at risk of post-operative confusion and attention problems. “Roughly half of seemingly normal older adults experience problems with thinking, memory or attention after surgery,” said Leah Acker, M.D., Ph.D., assistant professor in ...

Archaeologists unearth one of earliest known frame saddles

2023-12-12

In April 2015, looters sacked an ancient cave burial at a site called Urd Ulaan Uneet high within the Altai Mountains of western Mongolia. When police apprehended the criminals, they uncovered, among other artifacts, an elegantly carved saddle made from several pieces of birch wood. Now, in a new study, researchers from Mongolia collaborating with University of Colorado Boulder archaeologist William Taylor have described the find. The team’s radiocarbon dating pins the artifact to roughly the 4th Century ...

Spinning up control: Propeller shape helps direct nanoparticles, researchers say

2023-12-12

UNIVERSITY PARK, Pa. — Self-propelled nanoparticles could potentially advance drug delivery and lab-on-a-chip systems — but they are prone to go rogue with random, directionless movements. Now, an international team of researchers has developed an approach to rein in the synthetic particles. Led by Igor Aronson, the Dorothy Foehr Huck and J. Lloyd Huck Chair Professor of Biomedical Engineering, Chemistry and Mathematics at Penn State, the team redesigned the nanoparticles into a propeller shape to better control their movements and increase their functionality. ...

Karandeep Singh, MD, named inaugural Chief Health AI Officer at UC San Diego Health

2023-12-12

Karandeep Singh, MD, has been recruited as the Joan and Irwin Jacobs Endowed Chair in Digital Health Innovation at University of California School of Medicine and named as the inaugural chief health artificial intelligence (AI) officer at UC San Diego Health, a newly developed position for the region’s only academic medical center. This new role will be effective December 29, 2023. In this position, Singh will focus on implementing change that advances safety and health outcomes in acute and ambulatory settings. His contributions will be pivotal in bringing innovation to ...

Genetic safeguard protects some considered high risk for kidney disease

2023-12-12

NEW YORK, NY--Many Black Americans who are thought to have a high risk of developing kidney disease possess a protective genetic variant that nullifies the extra risk, a new study from Columbia researchers has found. The study found that high-risk people who carry this variant have a risk of developing kidney disease much closer to that of the general population. The findings will have an immediate impact on clinical practice, says study leader Simone Sanna-Cherchi, MD, associate professor of medicine at Columbia’s Vagelos College of Physicians and Surgeons. “Physicians ...

Liquid biopsy predicts immunotherapy response and toxicity in patients with advanced lung cancer

2023-12-12

FOR IMMEDIATE RELEASE Using a “liquid biopsy” to study genetic material from tumors shed into the bloodstream together with immune cells could help clinicians predict which patients with advanced lung cancers are responding to immunotherapies and which patients may develop immune-related side effects several months later, according to research directed by investigators at the Johns Hopkins Kimmel Cancer Center, the Bloomberg~Kimmel Institute for Cancer Immunotherapy and Allegheny Health Network Cancer Institute in Pittsburgh. By monitoring changes in circulating tumor DNA (ctDNA) among 30 patients treated with immunotherapies for metastatic non-small cell lung cancers, ...

Heavy metals in our food are most dangerous for kids

2023-12-12

WASHINGTON, DC, 2023, December 12, 2023 – The problem of foodborne metal contamination has taken on new urgency, thanks in part to a 2021 US Congressional Report detailing high levels of metals found in infant food pulled off grocery shelves. (More recently, high levels of lead were discovered in children’s fruit puree pouches.) Now, two new studies provide information on the correlation between exposure to heavy metals in food and the risk of cancers and other serious health risks. The findings will be presented ...

Artificial intelligence systems excel at imitation, but not innovation

2023-12-12

Artificial intelligence (AI) systems are often depicted as sentient agents poised to overshadow the human mind. But AI lacks the crucial human ability of innovation, researchers at the University of California, Berkeley have found. While children and adults alike can solve problems by finding novel uses for everyday objects, AI systems often lack the ability to view tools in a new way, according to findings published according to findings published in Perspectives on Psychological Science, a journal of ...

MSK’s Omar Abdel-Wahab honored for research targeting blood cancers

2023-12-12

Physician-scientist Omar Abdel-Wahab, MD, is being honored at the 2023 American Society of Hematology (ASH) Annual Meeting with the William Dameshek Prize, which recognizes individuals who have made outstanding contributions to the field of hematology. The award will be presented December 12. Dr. Abdel-Wahab, who chairs the Molecular Pharmacology Program at Memorial Sloan Kettering Cancer Center (MSK), was selected for his “trailblazing research” characterizing the genetic mutations that drive blood ...

Black individuals more likely to experience inequities in early diagnosis and treatment of Lyme disease, new research shows

2023-12-12

A new study out of the Johns Hopkins Medicine Lyme Disease Research Center has revealed disparities in the diagnosis and treatment of Lyme disease between Black and White patients with the condition. Researchers say the data, which draws on participants’ medical histories, whether from Johns Hopkins Medicine or other institutions, highlights issues in the nation’s medical education on Lyme disease. In the full article, published December 12 in JAMA Network Open, researchers say that Black patients were more likely to have advanced stages of Lyme disease when clinically diagnosed and also experience a longer time before receiving antibiotic treatment for the condition. Lyme ...

ASH: Mantle cell lymphoma patients see improved outcomes with oral combination of ibrutinib and venetoclax

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: